8-K - Citius Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Citius Pharmaceuticals, Inc. disclosed that its majority-owned subsidiary Citius Oncology, Inc. (Nasdaq: CTOR) announced positive topline Phase 1 data for LYMPHIR™ administered prior to commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory DLBCL patients, showing 86% ORR (57% CR, 29% PR), 77% one-year PFS, and 84% one-year OS with no dose-limiting toxicities.

Key Takeaways

1Citius Oncology issued press release on March 4, 2026, announcing Phase 1 topline results (NCT04855253)

2Trial enrolled 14 high-risk relapsed/refractory DLBCL patients at University of Minnesota and City of Hope

3LYMPHIR dosed at 5, 7, or 9 µg/kg prior to CAR-T (Yescarta, Breyanzi, or Kymriah); all patients completed treatment

486% ORR at one month (57% CR, 29% PR); 77% one-year PFS (95% CI: 43–92%); 84% one-year OS (95% CI: 49–96%)

5LYMPHIR well-tolerated with no DLTs; effective Treg depletion in 13/14 patients; manageable Grade 1-2 AEs

6Data presented at 2026 ASTCT & CIBMTR Tandem Meetings by Dr. Veronika Bachanova

Current Report Details

Event Type

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On March 4, 2026, Citius Oncology, Inc. (Nasdaq: CTOR), our majority-owned subsidiary, issued a press release announced positive topline safety an

Other Event

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated March 4, 2026. 104 Cover Page Interactive Data File, formatt

Exhibits Only

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE, DATED MARCH 4, 2026